Navigation Links
Premature Labor (Tocolysis) Therapeutic Pipeline Drugs and Companies Review H1 2015 Research Report Available at RnRMarketResearch.com
Date:3/12/2015

Dallas, Texas (PRWEB) March 13, 2015

The report “Premature Labor (Tocolysis) – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Male Hypogonadism. Premature Labor (Tocolysis) is labor that begins more than three weeks before you are expected to deliver your baby (but after the 24th week of pregnancy). If symptoms appear before 24 weeks, this is a threatened miscarriage and not preterm labour. The symptoms of Premature Labor (Tocolysis) include regular contractions for an hour, leaking or gushing of fluid from vagina, pain that feels like menstrual cramps, with or without diarrhea and a feeling of pressure in your pelvis or lower belly. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/premature-labor-tocolysis-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. Companies discussed in this Premature Labor (Tocolysis) – Pipeline Review, H1 2015 report include Actavis plc, GlaxoSmithKline plc, Kissei Pharmaceutical Co., Ltd., and ObsEva SA.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AT-814, bedoradrine sulfate, Drug for Postpartum Depression and Premature Labor, OBE-001, OBE-002, Progesterone Second Generation, retosiban and Small Molecule to Agonize Progesterone Receptor for Preterm Birth. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310184 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report include: Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor; Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221; Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound.

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Comparative Analysis by Unknown Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2015 17
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2015 18
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2015 39
Premature Labor (Tocolysis) - Dormant Projects, H1 2015 41
Premature Labor (Tocolysis) - Discontinued Products, H1 2015 42

List of Figures
Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 23
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Explore more reports on Women's Health Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/womens-health-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/premature-labor-tocolysis/pipeline-review-h1-2015/prweb12579845.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks
2. Premature Births Down in U.S., But Rates Still High, Reports Say
3. PTSD in Women Linked to Premature Birth
4. Gentle caffeine boost for premature babies
5. The viability of premature babies is minimal at 22 weeks gestation
6. A new therapeutic target may prevent blindness in premature babies at risk of retinopathy
7. Scientists map risk of premature menopause after cancer treatment
8. Human milk fat improves growth in premature infants
9. Heart rate variability may predict risk of disease in premature infants
10. Women repeatedly short-changed in case of premature ejaculation
11. Prevent premature deaths from heart failure, urges the Heart Failure Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology: